Article
Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab.
The Journal of infectious diseases - 1 Mar 2011
Zhu Qing, McAuliffe Josie M, Patel Nita K, Palmer-Hill Frances J, Yang Chin-fen, Liang Brandon, Su Lan, Zhu Wei, Wachter Leslie, Wilson Susan, MacGill Randall S, Krishnan Subramaniam, McCarthy Michael P, Losonsky Genevieve A, Suzich JoAnn A
Abstract excerpt
BACKGROUND: Palivizumab is a US Food and Drug Administration-approved monoclonal antibody for the prevention of respiratory syncytial virus (RSV) lower respiratory disease in high-risk infants. Motavizumab, derived from palivizumab with enhanced antiviral activity, has recently been tested in humans. Although palivizumab escape mutants have been generated in the laboratory, the development of resistant RSV in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.